Luye Pharma Group Ltd. Initiates Landmark U.S. Clinical Trial for Innovative CNS Drug LY03015

Key Developments That May Impact Shareholder Value

• First subject enrolled in U.S. pharmacokinetic (PK) bridging clinical trial for LY03015, an innovative CNS drug targeting tardive dyskinesia (TD) and Huntington’s disease (HD).
• LY03015 is the world’s first investigational drug designed to both inhibit VMAT2 and activate Sigma-1R, aiming to provide both symptom control and potential disease modification.
• The trial is a pivotal step towards U.S. Phase II and III studies and is also running in parallel in China, where Phase II completion is anticipated soon.
• Luye Pharma is strengthening its already differentiated CNS portfolio with this milestone, reinforcing its strategic focus in this therapeutic area.

In-Depth Details of the Announcement

Luye Pharma Group Ltd. has announced a significant advancement in its central nervous system (CNS) drug pipeline: the enrollment of the first subject in a U.S.-based pharmacokinetic (PK) bridging clinical trial for LY03015. This investigational drug is the first of its kind globally to combine dual mechanisms—inhibition of vesicular monoamine transporter 2 (VMAT2) and activation of the sigma-1 receptor (Sigma-1R).

LY03015 is being developed for the treatment of two challenging CNS disorders: tardive dyskinesia (TD) and Huntington’s disease (HD). Both conditions are characterized by involuntary movements and have high unmet medical needs. The drug’s dual action is designed to not only control symptoms but also potentially alter the underlying pathologies of these disorders.

• By inhibiting VMAT2, LY03015 decreases the release of presynaptic neuronal dopamine (DA), which is expected to reduce the overstimulation of D2 receptors—a mechanism linked to TD and HD symptoms—without directly blocking these receptors. This could offer symptom relief with a favorable side effect profile.
• By activating Sigma-1R, the drug may stimulate the release of brain-derived neurotrophic factor (BDNF) and promote synaptic remodeling. This could help restore impaired neural connectivity, offering sustained symptom control and potentially reducing relapse after treatment cessation.

The current U.S. trial is an open-label, single-dose, parallel-group study involving healthy Chinese and Caucasian adults. The primary objectives are to assess safety, tolerability, and PK profile, with the findings to guide dose selection for the next phase of U.S. clinical development (Phase II/III). The company expects to complete a Phase II clinical trial for LY03015 in China soon, further accelerating global development plans.

Market Context and Strategic Implications

Tardive dyskinesia (TD) is a serious movement disorder mainly caused by long-term use of dopamine receptor-blocking agents, including antipsychotics. It leads to permanent involuntary movements in up to 89% of affected patients, with an average prevalence of about 25.3% among those exposed to antipsychotics. Huntington’s disease (HD) is a genetic neurodegenerative disorder with symptoms of involuntary movements, cognitive decline, and psychiatric disturbances.

Currently, VMAT2 inhibitors are the only FDA-approved treatments for TD and HD, highlighting the urgent unmet need and market opportunity for new therapies. The development of LY03015 positions Luye Pharma at the forefront of this market with a potentially best-in-class and first-in-class therapy.

Luye Pharma’s Expanding CNS Portfolio

The CNS therapeutic area is a strategic priority for Luye Pharma. The company has already commercialized several CNS drugs:

• Erzofri® (paliperidone palmitate) extended-release injectable suspension and Rykindo® (risperidone) extended-release injectable suspension, both approved in the U.S.
• Rivastigmine Twice Weekly Transdermal Patch, approved in Japan, China, and multiple European markets.
• Ruoxinlin® (Toludesvenlafaxine Hydrochloride Sustained-Release Tablets), approved in China.
• Several other CNS drugs in clinical development, including LY03017 (targeting 5-HT2A/2C receptors), LY03020 (targeting TAAR1/5-HT2C receptors), and LY03021 (targeting GABA_AR/NET/DAT).

This diversified and innovative pipeline underpins Luye Pharma’s ambition to become a global leader in CNS therapeutics.

What Shareholders Should Watch

• The initiation of the U.S. PK bridging trial for LY03015 is a key inflection point that may catalyze further value creation if clinical results are positive and subsequent phases progress rapidly.
• Regulatory and clinical milestones in both the U.S. and China for LY03015 are potential share price catalysts, as the drug addresses large unmet needs in high-burden CNS disorders.
• Luye Pharma’s growing CNS portfolio and track record of international regulatory approvals reinforce its competitive positioning and growth outlook.

Leadership and Corporate Governance

The company’s Board is comprised of a mix of experienced executive, non-executive, and independent directors, guiding strategy and oversight as Luye Pharma expands its global clinical and commercial footprint.

Disclaimer: The above article is based on a company announcement and is intended for informational purposes only. It does not constitute investment advice. Investors should perform their own due diligence and consult professional advisors before making any investment decisions regarding Luye Pharma Group Ltd. or its securities. The information herein may contain forward-looking statements subject to risks and uncertainties.

View LUYE PHARMA Historical chart here